Motilal Oswal's research report on Apollo Hospitals
Ms. Reddy has reiterated the company’s commitment to reducing the losses in Healthco to zero by 4QFY24, thereby improving the overall profitability of APHS. APHS is making efforts to improve margins in new hospitals by optimizing the case mix and providing high-end tertiary treatment. APHS is strengthening its ‘IT’ backbone to gain a comprehensive database about patients and provide integrated healthcare services to them. We remain positive on APHS on the back of favourable demand tailwinds in the hospital segment and a robust outlook for offline/online pharmacies as well as diagnostic services. We expect a 20%/27% sales/EBITDA CAGR over FY23-25 for APHS.
Outlook
We arrive at a TP of INR5,580 by valuing APHS on the SOTP basis (EV/EBITDA of 23x for Healthcare Services, 13x for retained Pharmacy, 25x for front-end Pharmacy, and 20x for AHLL; 4x EV/sales for Apollo 24/7). Reiterate BUY.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.